Abstract Library

#4243 Role of gastric mucosa evaluation in diagnostic of pancreatic neuroendocrine tumors functional status

Introduction: Accessibility of high-precision imaging dramatically increased detection rate of small asymptomatic pancreatic neuroendocrine tumors (PanNETs). Functioning status is indication for surgical treatment with high perioperative risks, while increased level of NET markers could be associated with gastric mucosa atrophy or intake of proton pump inhibitors (PPI) and nor with tumor secretion.

Conference:

Presenting Author:

Authors: Salimgereeva D, Feidorov I, Konyakhina A,

Keywords: PanNET, chronic atrophic gastritis, marker, OLGA, anti-parietal cell antibodies,

#4234 Association of long-term PPI use with low-risk gastric neuroendocrine tumor

Introduction: Gastric neuroendocrine tumors are rare neoplasms, comprising approximately 2% of all gastric tumors, and develop from enterochromaffin-like (ECL) cells in the gastric mucosa. Type I and II develop due to hypergastrinemia and ECL cell hyperplasia; type III typically occurs sporadically, tend to be more aggressive, present metastatically in > 50% of cases, have normal fasting gastrin levels, and vary histopathologically from well- to poorly differentiated.

Conference:

Presenting Author: Al-Toubah T

Authors: Al-Toubah T, Pelle E, Haider M, Strosberg J,

Keywords: gastric, ppi, neuroendocrine, type 3 gastric net,

#4090 Octreotide infusion pump in patients with functional neuroendocrine tumors and refractory hormonal syndromes

Introduction: In patients with metastatic functional neuroendocrine tumors (NETs), symptoms are, sometimes, not adequately controlled with long-acting somatostatin analogues (LASSAs), so patients need to use boost subcutaneous (sc) octreotide injections (inj) daily. However, this approach is not always effective and convenient for the patients.

Conference:

Presenting Author: Thuringer J

Authors: Thuringer J, Parker G, Sarma A, Hayes A, Mandair D,

Keywords: carcinoid syndrome, VIPoma, Octreotide, pump, refractory, subcutaneous,

#3558 Association of long-term PPI use with low-risk gastric neuroendocrine tumor

Introduction: Gastric neuroendocrine tumors are rare neoplasms, comprising approximately 2% of all gastric tumors and develop from enterochromaffin-like (ECL) cells in the gastric mucosa. Type I and II develop due to hypergastrinemia and ECL cell hyperplasia; type III typically occure sporadically, tend to be more aggressive, present metastatically in > 50% of cases, have normal fasting gastrin levels, and vary histopathologically from well- to poorly differentiated tumors.

Conference:

Presenting Author:

Authors: Al-Toubah T, Pelle E, Strosberg J,

Keywords: gastric carcinoid, ppi, gastric, NET, type 2, type 3, type 1,

#3152 Vasostatin-1 as pancreatic neuroendocrine tumor (PanNET) biomarker: A comparison between preoperative and postoperative measurements

Introduction: No reliable biomarkers are currently available for pancreatic neuroendocrine tumors (PanNET). Vasostatin-1 (VS-1), the N-terminal fragment of Chromogranin A (CgA), seems to be more reliable than CgA as its plasma levels are not altered by proton pump inhibitors. An association between preoperative VS-1 and pathological features of aggressiveness was previously reported in a cohort of patients with resected nonfunctioning (NF)-PanNET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Manzoni M, Colombo B, Muffatti F,

Keywords: pancreatic neuroendocrine tumor, biomarker, chromogranin A, vasostatin-1,